Injectable atypical antipsychotics for agitation in borderline personality disorder

Pharmacopsychiatry. 2006 May;39(3):117-8. doi: 10.1055/s-2006-941489.

Abstract

Agitation is relatively common among Borderline Personality Disorder (BPD) patients in Psychiatric Emergency Services (PES). New injectable atypical antipsychotics are indicated for treatment in agitated psychotic or maniac patients but not for agitated BDP patients. Twenty agitated BPD patients were treated with intramuscular atypical antipsychotics (olanzapine or ziprasidone). Results suggest intramuscular atypical antipsychotics may be effective, fast and safe for treating acute BPD patients.

Publication types

  • Comparative Study
  • Letter

MeSH terms

  • Adult
  • Antipsychotic Agents / administration & dosage*
  • Benzodiazepines / administration & dosage
  • Bipolar Disorder / diagnosis
  • Bipolar Disorder / drug therapy
  • Borderline Personality Disorder / drug therapy*
  • Comorbidity
  • Emergency Services, Psychiatric
  • Female
  • Humans
  • Injections, Intramuscular
  • Male
  • Middle Aged
  • Olanzapine
  • Piperazines / administration & dosage*
  • Psychiatric Status Rating Scales
  • Psychomotor Agitation / drug therapy*
  • Psychotic Disorders / diagnosis
  • Psychotic Disorders / drug therapy
  • Schizophrenia / diagnosis
  • Schizophrenia / drug therapy
  • Thiazoles / administration & dosage*
  • Treatment Outcome

Substances

  • Antipsychotic Agents
  • Piperazines
  • Thiazoles
  • Benzodiazepines
  • ziprasidone
  • Olanzapine